

Amendments to the Claims:

This claim listing will replace all prior versions and listings of claims in the application:

Claim Listing:

1. (Currently amended) An oligonucleotide having a nucleotide sequence of from about 15 to about 26 nucleotides and having one or more phosphorothioate internucleoside linkage and being modified such that the terminal four nucleotides at the 5' end of the oligonucleotide and the terminal four nucleotides at the 3' end of the oligonucleotide each have 2'-O-methyl groups attached to their sugar residues, that inhibits the expression of one or more specific human histone deacetylase isoforms ~~selected from the group consisting of HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-6, HDAC-7 and HDAC-8~~, but less than all human histone deacetylase isoforms ~~selected from the group consisting of HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-6, HDAC-7 and HDAC-8~~, wherein the oligonucleotide hybridizes under physiological conditions through Watson-Crick or Hoogsteen base pairing to a region of RNA or double-stranded DNA that encodes a portion of HDAC-1 (SEQ ID NO: 2).
2. (Original) The oligonucleotide according to claim 1, wherein the oligonucleotide is a chimeric oligonucleotide.
3. (Original) The oligonucleotide according to claim 1, wherein the oligonucleotide is a hybrid oligonucleotide.
4. CANCELLED.
5. (CURRENTLY AMENDED) The oligonucleotide according to claim 1, being 20-26 nucleotides in length ~~and being modified such that the terminal four nucleotides at the 5' end of the oligonucleotide and the terminal four nucleotides at the 3' end of the oligonucleotide each have 2'-O-methyl groups attached to their sugar residues~~.
- 6-36. CANCELLED.